Distinguished Japanese professor Omura Satoshi won the Nobel prize for discovering a compound that led to the development of ivermectin. Now his university, Kitasato University Hospital, will conduct a major clinical trial to investigate whether the anti-parasite drug is a possible treatment for COVID-19. The university hospital will seek 240 COVID-19 patients aged 20 or over with mild to moderate symptoms. The intention for this study based on Japanese news: get this drug approved as an economical option to treat COVID-19.
The university formally established the basis for the study: University of Monash lab experiments revealing that ivermectin in cell culture kills ivermectin within 48 hours. Of course, TrialSite has published dozens of case series, observational studies and even the results of a couple randomized controlled studies evidencing promise for the low cost, available generic drug as a possible treatment for COVID-19. In fact, observational data reveals that ivermectin is more effective than Remdesivir, which hasn’t been able to impact COVID-19 mortality—at least not in randomized controlled studies.
But, of course, most of the world’s press doesn’t acknowledge the couple of randomized controlled studies involving ivermectin, reports NHK World Japan (Japan’s national broadcaster).
This randomized, controlled trial will include two groups including the ivermectin group and placebo group. The hospital seeks to assess the changes in symptoms to assess the safety and efficacy of ivermectin. The Japanese university seeks 240 patients with mild to moderate COVID-19.
Operated by the Kitasato Institute, this study seeks to example safety and efficacy to secure Japanese approval for ivermectin as a treatment against COVID-19.
The Trial Site
Kitasato University is a private medical university headquartered in Shirokane, Minato, Tokyo Japan. The university is ranked by Times Higher Education among the top 350 in Asia.
Kitasato University Hospital opened in 1971 as an academic medical center.
Note that Nobel prize winner Omura has served as deputy director at the Kitasato Institute; he was devoted to rebuild the laboratory while promoting the establishment of the medical center (now Kitasato University Medical Center).
TrialSite News Comments
The movement to test the safety and efficacy of ivermectin grows around the world. With nearly 40 randomized controlled studies ongoing in North America, Europe, South America and Asia major academic medical centers are embracing a growing body of real world data that ivermectin may in fact inhibit SARS-CoV-2 not only in vitro but potentially in vivo.